• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.异基因造血干细胞移植后骨髓再生不良期间的 SARS-CoV-2 病毒清除:一例报告。
Pediatr Transplant. 2021 Aug;25(5):e13875. doi: 10.1111/petr.13875. Epub 2020 Oct 12.
2
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.病例报告:SARS-CoV-2 阳性受者异基因造血干细胞移植的良好结局,感染与白血病之间的风险效益平衡。
Front Immunol. 2023 May 23;14:1184956. doi: 10.3389/fimmu.2023.1184956. eCollection 2023.
3
Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients.对异基因造血干细胞移植受者植入前发生的呼吸道合胞病毒感染进行成功的全身大剂量利巴韦林治疗。
Transpl Infect Dis. 2013 Aug;15(4):435-40. doi: 10.1111/tid.12092. Epub 2013 May 20.
4
Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes.异基因造血干细胞移植后呼吸道合胞病毒和人偏肺病毒:免疫缺陷评分指数、病毒载量和利巴韦林治疗对结局的影响。
Transpl Infect Dis. 2020 Aug;22(4):e13276. doi: 10.1111/tid.13276. Epub 2020 Apr 6.
5
Respiratory syncytial virus infection following hematopoietic stem cell transplantation.造血干细胞移植后的呼吸道合胞病毒感染
Bone Marrow Transplant. 2002 Feb;29(4):321-7. doi: 10.1038/sj.bmt.1703365.
6
Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.造血细胞移植受者接受雾化利巴韦林治疗呼吸道合胞病毒下呼吸道疾病的结果:干细胞来源和氧需求的意义。
Biol Blood Marrow Transplant. 2013 Apr;19(4):589-96. doi: 10.1016/j.bbmt.2012.12.019. Epub 2013 Jan 5.
7
[Nosocomial respiratory syncytial virus infections in three cases in a bone marrow transplantation unit].[骨髓移植病房3例医院获得性呼吸道合胞病毒感染]
Mikrobiyol Bul. 2008 Apr;42(2):359-64.
8
Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.造血细胞移植(HCT)后呼吸病毒肺炎:支气管肺泡灌洗液样本中病毒载量、血清样本中病毒 RNA 检测与 HCT 临床结局之间的关系。
J Infect Dis. 2010 May 1;201(9):1404-13. doi: 10.1086/651662.
9
Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.在异基因造血干细胞移植受者中有效使用利巴韦林治疗呼吸道合胞病毒感染。
J Hosp Infect. 2017 Feb;95(2):214-217. doi: 10.1016/j.jhin.2016.11.012. Epub 2016 Nov 25.
10
Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.口服利巴韦林治疗异基因造血干细胞移植后呼吸道合胞病毒下呼吸道感染并发闭塞性细支气管炎
Int J Hematol. 2011 Jan;93(1):132-4. doi: 10.1007/s12185-010-0756-9. Epub 2011 Jan 5.

引用本文的文献

1
COVID-19 infection in children with blood cancer: A systematic review.血癌患儿的新冠病毒感染:一项系统综述
Ann Hematol. 2025 Feb;104(2):1203-1230. doi: 10.1007/s00277-024-06057-4. Epub 2024 Nov 5.
2
Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis.COVID-19 大流行期间干细胞移植患者的特征与结局:一项系统综述和荟萃分析
Healthcare (Basel). 2024 Feb 23;12(5):530. doi: 10.3390/healthcare12050530.
3
Global Coinfections with Bacteria, Fungi, and Respiratory Viruses in Children with SARS-CoV-2: A Systematic Review and Meta-Analysis.2019冠状病毒病患儿的细菌、真菌和呼吸道病毒合并感染:一项系统评价和荟萃分析
Trop Med Infect Dis. 2022 Nov 15;7(11):380. doi: 10.3390/tropicalmed7110380.
4
The Global Impact of COVID-19 on Childhood Cancer Outcomes and Care Delivery - A Systematic Review.新冠病毒病对儿童癌症治疗结果及医疗服务提供的全球影响——一项系统综述
Front Oncol. 2022 Apr 7;12:869752. doi: 10.3389/fonc.2022.869752. eCollection 2022.
5
COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.儿童和青少年中的COVID-19:免疫功能正常和肿瘤血液学患者的特征及特异性
Mediterr J Hematol Infect Dis. 2022 Jan 1;14(1):e2022009. doi: 10.4084/MJHID.2022.009. eCollection 2022.
6
A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.造血干细胞移植患者中 SARS-CoV-2 感染的特征:系统文献复习。
Curr Oncol. 2022 Jan 13;29(1):337-349. doi: 10.3390/curroncol29010030.
7
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.COVID-19 与儿科癌症患者的治疗中断有关,但与短期死亡率无关:一项波兰全国性研究。
J Hematol Oncol. 2021 Oct 11;14(1):163. doi: 10.1186/s13045-021-01181-4.
8
A review on recipients of hematopoietic stem cell transplantation patients with COVID-19 infection.关于造血干细胞移植受者感染新型冠状病毒肺炎患者的综述。
Ther Adv Infect Dis. 2021 May 5;8:20499361211013252. doi: 10.1177/20499361211013252. eCollection 2021 Jan-Dec.
9
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review.儿童癌症与 COVID-19 患者的临床表现和结局:一项系统综述。
Pediatr Blood Cancer. 2021 Jun;68(6):e29005. doi: 10.1002/pbc.29005. Epub 2021 Mar 15.

本文引用的文献

1
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.羟氯喹或联合阿奇霉素治疗轻中度 COVID-19。
N Engl J Med. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak.新型冠状病毒肺炎大流行期间 SARS-CoV-2 和流感病毒合并感染患者的流行病学和临床特征。
J Med Virol. 2020 Nov;92(11):2870-2873. doi: 10.1002/jmv.26163. Epub 2020 Jul 6.
4
The First Pediatric Patients with Coronavirus Disease 2019 (COVID-19) in Japan: Risk of Co-Infection with Other Respiratory Viruses.日本首例儿童 2019 冠状病毒病(COVID-19)患者:与其他呼吸道病毒共同感染的风险。
Jpn J Infect Dis. 2020 Sep 24;73(5):377-380. doi: 10.7883/yoken.JJID.2020.181. Epub 2020 May 29.
5
SARS-CoV-2 and influenza virus co-infection.严重急性呼吸综合征冠状病毒2型与流感病毒合并感染
Lancet. 2020 May 16;395(10236):e84. doi: 10.1016/S0140-6736(20)31052-7. Epub 2020 May 5.
6
Co-infection with respiratory pathogens among COVID-2019 cases.COVID-19 病例中呼吸道病原体的合并感染。
Virus Res. 2020 Aug;285:198005. doi: 10.1016/j.virusres.2020.198005. Epub 2020 May 11.
7
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者:一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
8
First cases of COVID-19 in heart transplantation from China.中国心脏移植中首例新冠病毒病病例。
J Heart Lung Transplant. 2020 May;39(5):496-497. doi: 10.1016/j.healun.2020.03.006. Epub 2020 Mar 17.
9
Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.对《基于对来自中国武汉的150例患者数据的分析的2019冠状病毒病死亡的临床预测因素》的更正
Intensive Care Med. 2020 Jun;46(6):1294-1297. doi: 10.1007/s00134-020-06028-z.
10
COVID-19 virus and children: What do we know?新冠病毒与儿童:我们了解什么?
Arch Pediatr. 2020 Apr;27(3):117-118. doi: 10.1016/j.arcped.2020.03.001.

异基因造血干细胞移植后骨髓再生不良期间的 SARS-CoV-2 病毒清除:一例报告。

SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.

机构信息

Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland.

Department and Clinic of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland.

出版信息

Pediatr Transplant. 2021 Aug;25(5):e13875. doi: 10.1111/petr.13875. Epub 2020 Oct 12.

DOI:10.1111/petr.13875
PMID:32949079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7537051/
Abstract

Respiratory viral infections are known causes of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Here, we report a unique case of a child with viral pneumonia caused by coinfection with human metapneumovirus (MPV), respiratory syncytial virus (RSV), and SARS-CoV-2 after HSCT. A 9-year-old girl with acute lymphoblastic leukemia underwent allogeneic HSCT from a matched, unrelated donor. During the post-transplant period, in profound leukopenia (below 10 leukocytes/µL), she was diagnosed with SARS-CoV-2, MPV, and RSV pneumonia and was treated with ribavirin and chloroquine. Before leukocyte recovery, the girl became asymptomatic, and SARS-CoV-2 and RSV clearance was achieved. The shedding of SARS-CoV-2 stopped before immune system recovery, and one may hypothesize that the lack of an inflammatory response might have been a contributing factor to the mild clinical course. Post-transplant care in HSCT recipients with COVID-19 infection is feasible in regular transplant units, provided the patient does not present with respiratory failure. Early and repeated testing for SARS-CoV-2 in post-transplant patients with concomitant infection mitigation strategies should be considered in children after HSCT who develop fever, respiratory symptoms, and perhaps gastrointestinal symptoms to control the spread of COVID-19 both in patients and in healthcare workers in hospital environments. Training of staff and the availability of personal protective equipment are crucial for containing SARS-CoV-2 infection.

摘要

呼吸道病毒感染是异基因造血干细胞移植(HSCT)后死亡的已知原因。在这里,我们报告了一例异基因 HSCT 后由人类偏肺病毒(MPV)、呼吸道合胞病毒(RSV)和 SARS-CoV-2 合并感染引起病毒性肺炎的儿童独特病例。一名 9 岁女孩患有急性淋巴细胞白血病,接受了来自匹配的、无关供体的异基因 HSCT。在移植后期间,患儿出现严重白细胞减少症(白细胞计数低于 10/µL),被诊断为 SARS-CoV-2、MPV 和 RSV 肺炎,并接受利巴韦林和氯喹治疗。在白细胞恢复之前,女孩无症状,SARS-CoV-2 和 RSV 清除。在免疫系统恢复之前,SARS-CoV-2 的脱落停止,人们可能假设缺乏炎症反应是导致轻度临床病程的一个因素。在没有发生呼吸衰竭的情况下,COVID-19 感染的 HSCT 受者的移植后护理在常规移植单位是可行的。对于接受 HSCT 后出现发热、呼吸道症状且可能出现胃肠道症状的儿童,应考虑早期并重复检测 SARS-CoV-2,同时采取感染缓解策略,以控制 COVID-19 在患者和医院环境中的医护人员中的传播。工作人员的培训和个人防护设备的可用性对于控制 SARS-CoV-2 感染至关重要。